Drug Detail

Information about Glivec + Stivarga

Generic Name
 Imatinib + Regorafenib
IND
Brand Name (US)
 Glivec + Stivarga
Manufacturer
 Novartis + Bayer
Drug Type
Delivery
 Oral
Approval Status
 Both are approved. This combination is not approved for GIST. It is being evaluated in a phase 2 trial for GIST.
Indications
Overall Strategy
Strategy
Drug Category
 KIT/PDGFRA inhibitor + VEGF inhibitor

According to ALT GIST Study Chair, Dr. Desmond Yip, the rationale for this combination is, " . . . an alternating regimen of imatinib and regorafenib with brief drug-free intervals may allow tumour stem cells to re‐enter the cell cycle and become susceptible once more to drug therapy."

Links

 

 See imatinib
   

 

 See regorafenib
   

 

 ALT GIST opens first Australian site
   

Trials of this drug

  

 A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) (ALT GIST)
   

Trial results
  ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).
   

Search for this drug/combination in:

ClinicalTrials.gov

ASCO

Pubmed